EIM
PCRX icon

Essex Investment Management’s Pacira BioSciences PCRX Stock Holding History

Essex Investment Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-6,306
Closed -$334K – 336
2016
Q1 		$334K Sell
6,306
-1,900
-23% -$111K 0.06% 276
2015
Q4 		$630K Buy
+8,206
New +$465K 0.1% 213

Other funds holding PCRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Essex Investment Management's PCRX Position: Q2 2016 in Review

Essex Investment Management sold out of Pacira BioSciences (PCRX) in Q2 2016, closing a stake of 6,306 shares — an estimated $334K sold.

Essex Investment Management first reported a position in PCRX in Q4 2015 and held it in 2 quarters. The position peaked at $630K in Q4 2015. 183 funds tracked by Wall St. Rank hold PCRX as of Q2 2016.

  • Essex Investment Management reported no remaining Pacira BioSciences position as of Q2 2016 after selling out during the quarter.
  • Essex Investment Management sold 6,306 Pacira BioSciences shares in Q2 2016, an estimated $334K.
  • Essex Investment Management first reported a position in Pacira BioSciences in Q4 2015 and held it in 2 quarters.
  • Essex Investment Management's Pacira BioSciences position peaked at $630K in Q4 2015.
  • 183 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2016.

Based on Essex Investment Management's 13F filing for Q2 2016, filed 27 Jul 2016.